The serum sPD‐L1 level has been reported to be upregulated in patients with elevated markers of systemic inflammation, such as CRP, in hepatocellular carcinoma (HCC),31 gastric cancer,18 or pancreatic cancer.24 Here, SPDL1 is linked to pancreatic neoplasm.